As shown in Fig. 3, allo-HSCT significantly improved the OS (median 29.53 months vs. 11.33 months, P = 0.008, Fig. 3A) and EFS (median 29.53 months vs. 8.53 months, P = 0.007, Fig. 3B) in double or triple-hit ASXL1+ AML patients. Here, ASXL1 is linked to acute myeloid leukemia.